Lancet Diabetes Endocrinol

Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials.

Vale C, Godolphin PJ, Fisher D, ..., Shankar-Hari M, WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Lancet Diabetes Endocrinol 12 (10) 735-747 [2024-10-00; online 2024-09-06]

Category: Drug Discovery Type: Journal article

Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.

Kosiborod MN, Esterline R, Oscarsson J, ..., Verma S, Berwanger O

Lancet Diabetes Endocrinol - (-) - [2021-12-15; online 2021-12-15]

Type: Other

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Kosiborod MN, Esterline R, Furtado RHM, ..., Nigro Maia L, Berwanger O

Lancet Diabetes Endocrinol - (-) - [2021-07-21; online 2021-07-21]

Category: Biochemistry Category: Drug Discovery Type: Journal article

Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.

Jolliffe DA, Camargo CA, Sluyter JD, ..., Urashima M, Martineau AR

Lancet Diabetes Endocrinol - (-) - [2021-03-30; online 2021-03-30]

Category: Health Type: Journal article